Pre-earnings options volume in CTI BioPharma is 1.7x normal with calls leading puts 16:1. Implied volatility suggests the market is anticipating a move near 9.1%, or 46c, after results are released. Median move over the past eight quarters is 8.5%.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CTIC:
- CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results
- CTI BioPharma reports Q4 EPS (14c), consensus (10c)
Questions or Comments about the article? Write to editor@tipranks.com